A groundbreaking trial of an interactive, gamified neurotechnology has demonstrated significant potential as a transformative treatment for chronic nerve pain. Developed by a dedicated team of researchers at UNSW Sydney, the technology—known as "PainWaive"—teaches patients how to consciously regulate abnormal brain activity associated with neuropathic pain. By offering a non-invasive, at-home alternative to traditional pharmacological interventions, this innovation provides a glimmer of hope for the millions of people who struggle with the debilitating effects of chronic pain and the potential risks associated with long-term opioid use.
The technology is the result of years of interdisciplinary collaboration led by Professor Sylvia Gustin and Dr. Negin Hesam-Shariati from UNSW Sydney’s NeuroRecovery Research Hub. The initial findings, which have been published in the Journal of Pain, suggest that the brain-computer interface (BCI) approach could fundamentally change how clinicians approach pain management. By allowing users to monitor and adjust their own neural patterns in real-time, PainWaive empowers patients to take an active role in their recovery within the comfort of their own homes.
Understanding the Neurological Roots of Pain
The PainWaive project is rooted in the pioneering research of Professor Gustin, who has spent years investigating the structural and functional changes in the brain’s thalamus—a central relay hub that processes sensory information—in patients suffering from chronic nerve pain. Her work has identified a distinct, identifiable "signature" of brain activity in individuals with neuropathic conditions.
"The brainwaves of people with neuropathic pain show a distinct pattern: more slow theta waves, fewer alpha waves, and more fast, high beta waves," Professor Gustin explains. "We believe these changes interfere with how the thalamus talks to other parts of the brain, especially the sensory motor cortex, which registers pain."
For those living with nerve damage, these abnormal oscillations are not merely a byproduct of the condition but are believed to be central to the maintenance of the pain signal itself. When the sensory motor cortex is bombarded by these erratic signals, the brain struggles to process sensory inputs correctly, leading to the persistent, often agonizing sensations that characterize chronic neuropathic pain. Recognizing this, Professor Gustin posed a critical question: could a treatment be developed that specifically targets and normalizes these irregular wave patterns, effectively "retuning" the brain to a healthier state? This question served as the catalyst for the development of PainWaive.
A Pilot Trial of At-Home Neuro-Regulation
To test this hypothesis, the research team recruited participants for a pilot study. Each participant was provided with a specialized kit containing a bespoke EEG headset and a tablet pre-loaded with the PainWaive application. The app functions as an interactive game that provides users with immediate feedback on their neural activity. By using various mental strategies—such as focusing on happy memories, practicing deep relaxation, or employing specific visualization techniques—participants learn to manipulate their brain waves to achieve a more "normal" state.
The study monitored participants over a four-week period. Throughout the trial, the researchers tracked a wide array of metrics, including the severity of the pain, the degree of pain interference in daily life, and the underlying brainwave patterns captured by the EEG headsets. The system was designed to provide real-time responses to shifts in brain activity, allowing users to see the direct result of their mental efforts on the game interface.
The results were striking. Among the four participants involved in the initial trial, three reported significant reductions in their pain levels, with the most pronounced improvements observed toward the end of the four-week regimen. Perhaps most importantly, the level of relief achieved by these participants was found to be comparable to, or in some instances, greater than the relief typically offered by conventional opioid treatments.
Despite the encouraging data, the research team remains cautious and scientific in their appraisal of the results. "Restrictions in the study’s size, design and duration limit our ability to generalise the findings or rule out placebo effects," acknowledges Dr. Hesam-Shariati. However, she notes that the outcomes are sufficiently robust to justify the next phase of the research, which will involve a much larger cohort of patients.
Empowerment Through Technology and Design
One of the most significant aspects of the PainWaive project is its focus on accessibility and patient autonomy. Many existing neuro-feedback systems are either prohibitively expensive or require constant oversight by medical professionals in clinical settings. From the outset, the UNSW team was determined to create a solution that was not only effective but also practical for daily use.
Initially, the researchers explored the use of commercial EEG systems. However, they found that these devices were either far too costly or lacked the signal quality required to provide the precise feedback necessary for the PainWaive game. Faced with these limitations, the team took the ambitious step of developing their own hardware.
"Everything except the open-source EEG board was built in-house," Dr. Hesam-Shariati says. "And soon, even that will be replaced by a custom-designed board." By leveraging 3D printing technology, the team has managed to reduce the cost of producing each headset to approximately $300. This is a dramatic reduction compared to existing medical-grade systems, which can range in price from $1,000 to $20,000.
The headset is designed with a saline-based wet electrode system, which enhances signal quality by ensuring better contact with the scalp, specifically targeting the sensorimotor cortex. Furthermore, the team worked closely with patients during the design process to ensure that the device was lightweight, comfortable, and easy to operate.
"After just a couple of Zoom sessions, participants were able to run the treatment entirely on their own," Dr. Hesam-Shariati notes. "Participants felt empowered to manage their pain in their own environment. That’s a huge part of what makes this special." This sense of agency is vital for patients with chronic pain, who often feel that they have lost control over their bodies and their quality of life. By shifting the power to manage pain from the doctor’s office to the patient’s home, PainWaive represents a significant step forward in patient-centered care.
The Path Forward
The research team at UNSW Sydney and Neuroscience Research Australia (NeuRA) is now focused on scaling their efforts. With the success of the initial pilot, they are moving forward with two upcoming, larger-scale trials. The first, the Spinal Pain Trial, will specifically investigate the effectiveness of the technology in reducing chronic spinal pain. The second, the StoPain Trial, will evaluate its application in treating chronic neuropathic pain specifically among individuals living with spinal cord injuries.
As the team prepares for these expanded trials, they remain committed to the vision of making PainWaive a standard, affordable, and accessible tool for pain management globally. For the many individuals for whom traditional medications provide insufficient relief or cause intolerable side effects, the prospect of a drug-free, brain-training solution offers a transformative potential. By normalizing the brain’s own signals, the researchers believe they have tapped into a new frontier of medicine—one that trusts the brain’s inherent ability to heal and regulate itself when provided with the right tools and information.
While there is still much to learn about the long-term efficacy and generalizability of the PainWaive technology, the preliminary results have provided a solid foundation for further inquiry. As the research continues, the team remains hopeful that this interdisciplinary approach—combining neurobiology, gaming, and 3D printing—will provide a meaningful, sustainable path forward for those living in the shadow of chronic nerve pain. The researchers are currently calling for interested participants to join the upcoming trials, marking a significant step toward bringing this innovative technology out of the lab and into the lives of the people who need it most.